The Medicines Company
Founded Year
1996Stage
Acq - P2P | AcquiredTotal Raised
$100.78MValuation
$0000About The Medicines Company
The Medicines Company's purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on 3,000 leading acute/intensive care hospitals worldwide. The company's vision is to be a leading provider of solutions in three areas: acute cardiovascular care, surgery and perioperative care, and serious infectious disease care.
Missing: The Medicines Company's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: The Medicines Company's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing The Medicines Company
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
The Medicines Company is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
The Medicines Company Patents
The Medicines Company has filed 60 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
8/2/2016 | 6/7/2022 | Adenosine receptor antagonists, Heart diseases, Cardiac arrhythmia, Cardiac procedures, Ischemic heart diseases | Grant |
Application Date | 8/2/2016 |
|---|---|
Grant Date | 6/7/2022 |
Title | |
Related Topics | Adenosine receptor antagonists, Heart diseases, Cardiac arrhythmia, Cardiac procedures, Ischemic heart diseases |
Status | Grant |
Latest The Medicines Company News
May 12, 2021
| The Medicines Company, Urigen Pharmaceuticals, Boehringer Ingelheim, BMS & so on… Oral Anticoagulants market players – The Medicines Company, Urigen Pharmaceuticals, Boehringer Ingelheim, BMS, among others represent the global Oral Anticoagulants market . The market study depicts an extensive analysis of all the players running in the Oral Anticoagulants market report based on distribution channels, local network, innovative launches, industrial penetration, production methods, and revenue generation. Further, the market strategies and mergers & acquisitions associated with the players are enclosed in the Oral Anticoagulants market report. Future Market Insights, in its latest business report, elaborates on the current situation of the global Oral Anticoagulants market in terms of volume, value, production, and consumption. The report scrutinizes the market into various segments, end uses, regions, and players on the basis of demand patterns, and future prospects. Ask an Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-6587 Proximal deep vein thrombosis (DVT) Arterial and venous thrombosis Others On the basis of Distribution Channels, the global Oral Anticoagulants market report covers the key segments, such as Hospital Pharmacies What key insights does the Oral Anticoagulants market research provide? Historical and current year revenue of related Oral Anticoagulants market players analyzed at the regional level. One by one company profile of prominent stakeholders. Analysis of the Oral Anticoagulants market size on the basis of product type and end-use type. Accurate Oral Anticoagulants market forecast in terms of value and volume in numbers and percentages. Demand prospect of each segment covered in the report. Ask for TOC @ https://www.futuremarketinsights.com/toc/rep-gb-6587 How the market for Oral Anticoagulants is expected to shape in the coming ten years? What strategies are the Oral Anticoagulants market vendors implementing to stay ahead of their rivals? Why are consumers shifting towards alternative Oral Anticoagulants products? What innovative technologies are the Oral Anticoagulants players using to get an edge over their rivals? What are the restraints affecting the growth of the global Oral Anticoagulants market? The Oral Anticoagulants market study considers the following years to project the overall market growth: History Year: 2014 – 2018 Modern technologies, such as artificial intelligence, to provide updated industry trends. Data collection from implementation vendors, service providers, and raw material suppliers to provide a clear perspective. Interaction with research scientists and development heads to understand the nature of the market more precisely. Three-step quality check process – Data collection, triangulation, and validation. 24/7 availability of services. Explore Wide-ranging Coverage of FMI’s Healthcare Market Insights Landscape Folliculotropic Mycosis Fungoides Treatment Market FMI’s analysis gives an insight into key market trends, strategies, regional players and various segments on the basis of form, type, application and region. Nose Reconstruction Market Find insights into global market scenario and segmentation on the basis of ingredients, application, source and region. Porokeratosis treatment Market FMI’s report highlights parent market trends and strategies in the market with segments and dynamics through the forecast period. About us Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers. Contact us Jumeirah Lakes Towers, Dubai, PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings. The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. follow us Version: 2021.4.7.1 You are leaving PharmiWeb.com Disclaimer: You are now leaving PharmiWeb.com website and are going to a website that is not operated by us. We are not responsible for the content or availability of linked sites. ABOUT THIRD PARTY LINKS ON OUR SITE PharmiWeb.com offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links you will leave the PharmiWeb.com website and will be redirected to another site. These sites are not under the control of PharmiWeb.com. PharmiWeb.com is not responsible for the content of linked third party websites. We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information. Also, please be aware that the security and privacy policies on these sites may be different than PharmiWeb.com policies, so please read third party privacy and security policies closely. If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly. Continue
The Medicines Company Frequently Asked Questions (FAQ)
When was The Medicines Company founded?
The Medicines Company was founded in 1996.
Where is The Medicines Company's headquarters?
The Medicines Company's headquarters is located at 8 Sylvan Way, Parsippany.
What is The Medicines Company's latest funding round?
The Medicines Company's latest funding round is Acq - P2P.
How much did The Medicines Company raise?
The Medicines Company raised a total of $100.78M.
Who are the investors of The Medicines Company?
Investors of The Medicines Company include Novartis, Warburg Pincus, Alta Partners, QHP Capital, Deerfield Management and 16 more.
Who are The Medicines Company's competitors?
Competitors of The Medicines Company include Ra Pharmaceuticals, SynDevRx, Milestone Pharmaceuticals, NanoString Technologies, Entelos and 10 more.
Compare The Medicines Company to Competitors
Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.
Konova offers anti-obesity drug development
SynDevRx has developed a technology that increases the activity and safety of small molecule drugs using a conjugation technique. The company's technology increases a drug's therapeutic index by concentrating activity at the disease site. It provides small molecules with predictable and reliable physical properties that can speed up development time and lower costs while improving the PK profile. SynDevRx's lead drug candidate SDX-7320 targets the oncology market and inhibits MetAP2 - an enzyme that independent research has shown to be key to tumor growth, proliferation, and metastasis. The company was founded in 2007 and is based in Cambridge, Massachusetts.
Cellogico Simulations Allow More Efficient Use Of Resources Through Highlighting Drug Targets With The Greatest Chance Of Success In The Early Stage Of Drug Development.
Auxeris Therapeutics, Inc. is engaged in osteoporosis drug development
QPS is a GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services. Focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.